InnerMedical Secures Hundreds of Millions RMB in Series C Funding to Advance Minimally Invasive Imaging and Therapeutic Devices

Shenzhen Innermedical Medical Technology Co., Ltd. (hereinafter referred to as “Innermedical”) has recently completed a C-round financing of over RMB 100 million. The round was led by CAS Star Capital, with participation from existing and new investors including Yifeng Capital, Shenzhen High-Tech Investment Group, Xiantong Capital, Guiyang Venture Capital, and Jinan University Asset Management. The funds raised will be primarily used for the development of products under research, as well as for market launch, promotion, and commercialization.

Innermedical, established in 2015, has evolved over six years into an innovative high-tech medical enterprise integrating R&D, manufacturing, and sales. Adhering to a platform-based technological development strategy, Innermedical focuses on optical, ultrasound, and energy-based technologies, specializing in minimally invasive interventional devices for gastroenterology and cardiology. Its core product portfolio includes imaging equipment and consumables such as endoscopic ultrasound systems, vascular imaging systems, and electronic endoscopes, as well as high-end active therapeutic devices for interventional procedures.

As population aging intensifies, cancer and cardiovascular and cerebrovascular diseases have become the leading causes of death and major health concerns. In the corresponding fields of diagnosis and treatment, there remains a substantial need for innovative products to meet clinical demands. Innermedical continues to develop innovative imaging equipment and high-end therapeutic devices for major diseases such as cancer and cardiovascular and cerebrovascular conditions, striving to provide comprehensive solutions for minimally invasive interventional procedures.

Guangdong Zhongke Kechuang Venture Capital Management Co., Ltd. (hereinafter referred to as “Zhongke Kechuang”) was established on July 15, 2009. Under the guidance and support of the Guangdong Provincial Committee of the Communist Party of China and the Guangdong Provincial People’s Government, it settled in Guangzhou as the sponsor and manager of the Zhongke Baiyun Equity Investment Fund, the first large-scale filed equity investment fund in Guangdong Province.

In March 2014, Zhongke Kechuang was granted the Private Investment Fund Manager Certificate by the Asset Management Association of China (AMAC), becoming one of the first batch of asset management institutions in China authorized to engage in private equity investment management activities, including equity investment and venture capital. In 2017, it became one of the managers for the Guangxi Government’s Fiscal Guidance Fund of Funds. Zhongke Kechuang oversees multiple subsidiary platforms, including Guangdong Zhongguang Investment Co., Ltd., Zhongke Wotu Fund Management Co., Ltd., and Guangdong Zhongke Lingyi Industrial Growth Base Asset Management Co., Ltd., along with a specialized investment management team of nearly 200 professionals. The company also serves as an Executive Vice President Unit of the Guangdong Venture Capital Association and a Co-Chairman Unit of the Guangzhou Equity Investment Industry Association.

Yifeng Capital is a specialized firm focused on venture capital (VC) and private equity (PE) investments in the biopharmaceutical sector. Leveraging a global perspective, it deeply explores and integrates biopharmaceutical project resources. Its investment team is led by PhDs in biopharmaceutical sciences from top-tier universities in China, the United States, Europe, Japan, and other regions, achieving a global layout in both talent structure and project resources. Owing to its outstanding investment performance and excellent investment research capabilities, Yifeng Capital has received accolades such as “China’s Most Dynamic Drug Innovation Investment Firm” and “China’s Best Emerging VC Manager,” and has been consecutively rated as one of the “Top Ten Venture Capital Firms in Shenzhen” for many years. It has also been featured and interviewed by Nature, a world-renowned scientific journal. Yifeng Capital has conducted rigorous screening and invested in more than twenty high-quality domestic and overseas enterprises, including Mindray Medical, Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Pumen Technology, Apexigen, and Centrexion.

Xiantong Capital is one of China’s earliest established, globally operating specialized biomedical venture capital firms. Focused on the life sciences sector, it holds a leading professional advantage and boasts extensive project resources within the biomedical investment industry. Rooted in the most promising industries, Xiantong Capital identifies innovative high-growth enterprises with significant capital value and commercial potential, cultivating a cohort of benchmark companies in niche sectors.

Xiantong Capital maintains offices in Shenzhen, Beijing, Suzhou, and Chicago. It has assembled an investment and advisory team comprising industry experts, scientists, and investors from the life sciences and technology sectors, and manages and operates a series of RMB and USD funds.

Shenzhen High-Tech Investment Group Co., Ltd. (hereinafter referred to as “Shenzhen HTI”) was established in December 1994. It is a professional financial services institution founded by the Shenzhen Municipal Committee of the Communist Party of China and the Shenzhen Municipal People’s Government in the early 1990s to address the financing difficulties faced by small and medium-sized technology enterprises. It has since developed into a “national innovative financial services group with the highest AAA credit rating from capital market entities.”

Guiyang Venture Capital Co., Ltd. (hereinafter referred to as “Guiyang VC”) is a venture capital investment enterprise approved and established by the Guiyang Municipal People’s Government. Founded in 2010, the company’s current shareholders are Guiyang Industrial and Commercial Investment Group Co., Ltd. and Guiyang Wudang District State-owned Assets Operation Company, with a registered capital of RMB 350 million. It has been honored as the “2017 China Best Government Industry Guidance Fund” and one of Guizhou Province’s “2018 Leading Enterprises.” Guiyang VC manages nine funds with total assets under management exceeding RMB 4 billion; these funds include government guidance funds and mixed-ownership venture capital funds. As a specialized VC+FOF (Fund of Funds) investment management institution, Guiyang VC is committed to supporting the rapid growth of small and medium-sized enterprises (SMEs) in their startup and growth stages that possess unique competitive advantages, aiming to serve as an incubator and accelerator for entrepreneurial ventures.